抗抑郁药选择的循证标准

A. Serretti
{"title":"抗抑郁药选择的循证标准","authors":"A. Serretti","doi":"10.5350/DAJPN20173001001","DOIUrl":null,"url":null,"abstract":"Antidepressant drugs are, according to some estimates, the most widely prescribed class of drugs in the population with 253.6 million prescriptions in 2010 in the United States of America (1). This capacity is due to a number of factors including a wide range of indications and an overall good tolerability. Therefore antidepressants are currently prescribed very frequently by physicians, also recommended by non psychiatrists. The success of antidepressants led to the development of many new compounds over the last decades and we are now able to use more than 40 licensed compounds licensed in the treatment of depression. The availability of so many compounds is positive on one hand, because of the possibility to choose within a wide range of different compounds; but on the other hand it causes confusion for the clinician, who may not be aware of the differences across so many apparently similar drugs. As a result, in the clinical practice many psychiatrists usually prescribe only a small number of compounds which they are familiar with and never or seldom take into consideration other compounds. It is not exceptional to encounter colleagues who prescribe just 2 or 3 different antidepressants, therefore neglecting a wide range of other compounds which could be better suited for their patients. Therefore, the big challenge, which is the main aim of this editorial, is to solicit the awareness within psychiatrist of the whole range of therapeutic possibilities that we have. In fact, on the contrary to what is currently believed, antidepressants are very different one from another and the selection should be performed with great care taking into consideration a wide range of evidence based factors.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evidence Based Criteria for the Antidepressant Choice\",\"authors\":\"A. Serretti\",\"doi\":\"10.5350/DAJPN20173001001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antidepressant drugs are, according to some estimates, the most widely prescribed class of drugs in the population with 253.6 million prescriptions in 2010 in the United States of America (1). This capacity is due to a number of factors including a wide range of indications and an overall good tolerability. Therefore antidepressants are currently prescribed very frequently by physicians, also recommended by non psychiatrists. The success of antidepressants led to the development of many new compounds over the last decades and we are now able to use more than 40 licensed compounds licensed in the treatment of depression. The availability of so many compounds is positive on one hand, because of the possibility to choose within a wide range of different compounds; but on the other hand it causes confusion for the clinician, who may not be aware of the differences across so many apparently similar drugs. As a result, in the clinical practice many psychiatrists usually prescribe only a small number of compounds which they are familiar with and never or seldom take into consideration other compounds. It is not exceptional to encounter colleagues who prescribe just 2 or 3 different antidepressants, therefore neglecting a wide range of other compounds which could be better suited for their patients. Therefore, the big challenge, which is the main aim of this editorial, is to solicit the awareness within psychiatrist of the whole range of therapeutic possibilities that we have. In fact, on the contrary to what is currently believed, antidepressants are very different one from another and the selection should be performed with great care taking into consideration a wide range of evidence based factors.\",\"PeriodicalId\":136580,\"journal\":{\"name\":\"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5350/DAJPN20173001001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5350/DAJPN20173001001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

据估计,抗抑郁药是美国2010年处方量最大的一类药物,处方量为2.536亿(1)。这是由于多种因素造成的,包括适应症范围广,总体耐受性好。因此,抗抑郁药目前经常被医生开处方,也被非精神科医生推荐。在过去的几十年里,抗抑郁药的成功导致了许多新化合物的开发,我们现在能够使用超过40种许可的化合物来治疗抑郁症。这么多化合物的可用性一方面是积极的,因为可以在广泛的不同化合物范围内进行选择;但另一方面,这给临床医生带来了困惑,他们可能没有意识到这么多表面上相似的药物之间的差异。因此,在临床实践中,许多精神科医生通常只开少量他们熟悉的化合物,从不或很少考虑其他化合物。经常会遇到同事只开2到3种不同的抗抑郁药,从而忽略了其他更适合他们病人的化合物。因此,最大的挑战,也是这篇社论的主要目的,是让精神科医生意识到我们所拥有的所有治疗可能性。事实上,与目前所认为的相反,抗抑郁药是非常不同的,在选择时应该非常小心,考虑到广泛的基于证据的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evidence Based Criteria for the Antidepressant Choice
Antidepressant drugs are, according to some estimates, the most widely prescribed class of drugs in the population with 253.6 million prescriptions in 2010 in the United States of America (1). This capacity is due to a number of factors including a wide range of indications and an overall good tolerability. Therefore antidepressants are currently prescribed very frequently by physicians, also recommended by non psychiatrists. The success of antidepressants led to the development of many new compounds over the last decades and we are now able to use more than 40 licensed compounds licensed in the treatment of depression. The availability of so many compounds is positive on one hand, because of the possibility to choose within a wide range of different compounds; but on the other hand it causes confusion for the clinician, who may not be aware of the differences across so many apparently similar drugs. As a result, in the clinical practice many psychiatrists usually prescribe only a small number of compounds which they are familiar with and never or seldom take into consideration other compounds. It is not exceptional to encounter colleagues who prescribe just 2 or 3 different antidepressants, therefore neglecting a wide range of other compounds which could be better suited for their patients. Therefore, the big challenge, which is the main aim of this editorial, is to solicit the awareness within psychiatrist of the whole range of therapeutic possibilities that we have. In fact, on the contrary to what is currently believed, antidepressants are very different one from another and the selection should be performed with great care taking into consideration a wide range of evidence based factors.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信